All In Biotech

Drug Trial Radar · NCT07900867

This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SSGJ-626 in Participants With Active Cutaneous Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2028

Study completion Aug 2029

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

Conditions

  • Cutaneous Lupus Erythematosus (CLE)

Interventions

  • PlaceboDrug

    Placebo subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 24Time frame: Baseline to Week 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College.

    Nanjing, Jiangsusheng, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.